Page 2 - Multifactorial Adaptive Platform Trial For Community News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19

This exploratory study of a multiplatform randomized trial investigating the effects of therapeutic-dose heparin in early-pandemic hospitalized COVID-19 patient

United statesNew zealandProvince of ontarioWestern australiaBruxelles capitaleChristopher seymourMonte carloMeredian bioEwanc goligherLyonelg israels researchMultifactorial adaptive platform trial for communityGlobal coalition for adaptive researchUniversity of marylandBoehringer ingelheimAustralian national healthAmag pharmaceuticals

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA

This randomized clinical trial assesses the effect of treatment with an antiplatelet agent vs no antiplatelet therapy on days alive and free of intensive care u

Nordrhein westfalenCity ofUnited kingdomFrance generalBritish columbiaUnited statesBedford parkSouth australiaFlinders universityWestern australiaSan franciscoNew zealand generalNew zealandEstado de pernambucoNational university of singaporeSingapore general

Anticoagulants Help Moderately Ill COVID-19 Patients

Anticoagulants Help Moderately Ill COVID-19 Patients
medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.

Ambarish pandeyMultifactorial adaptive platform trial for communityNew england journalAssistant professorInternal medicineAntithrombotic therapyAmeliorate complicationsRandomized controlled platform trialAntithrombotic strategiesHospitalized adultsMultifactorial adaptive platform trialCommunity acquired pneumoniaChance of heart attack andWith problemsDiet planLifestyle modifications

Therapeutic-dose anticoagulation benefits moderately ill COVID-19 patients

Moderately ill patients hospitalized with COVID-19 have better chances of survival if treated with therapeutic-dose anticoagulation, according to an international study involving 121 sites, including UT Southwestern Medical Center.

United statesAmbarish pandeyEmily hendersonTexas health resources clinical scholarUt southwestern medical centerMultifactorial adaptive platform trial for communityAssistant professorInternal medicineNew england journalAntithrombotic therapyAmeliorate complicationsRandomized controlled platform trialAntithrombotic strategiesHospitalized adultsMultifactorial adaptive platform trialCommunity acquired pneumonia

Anticoagulants help moderately ill Covid patients

Anticoagulants help moderately ill Covid patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesAmbarish pandeyNational academy of sciencesTexas health resources clinical scholarUt southwestern medical centerMultifactorial adaptive platform trial for communityHoward hughes medical institute investigatorsNational academy of medicineAssistant professorInternal medicineNew england journalAntithrombotic therapyAmeliorate complicationsRandomized controlled platform trialAntithrombotic strategiesHospitalized adults